Xylistin Injection (1MIU) is a pharmaceutical formulation containing Colistimethate Sodium, which is equivalent to 1 million international units (IU). This medication is primarily used for the treatment of serious infections caused by multidrug-resistant Gram-negative bacteria, particularly in patients with compromised immune systems or those undergoing intensive care. Xylistin works by disrupting the bacterial cell membrane, leading to cell death, making it an essential option in the fight against antibiotic-resistant infections. The composition of Xylistin Injection includes Colistimethate Sodium, which is a prodrug that is converted to colistin in the body, exerting its antimicrobial effects. This injection is typically administered intravenously, allowing for rapid absorption and effectiveness in treating severe infections. As antibiotic resistance continues to rise, Xylistin Injection plays a crucial role in modern medicine, providing a vital treatment option for patients facing life-threatening infections.